Overview

Adaptive Efficacy and Safety Study of Glenzocimab Used as an add-on Therapy on Top of Standard of Care un the 4.5 Hours Following an Acute Ischemic Stroke

Status:
Recruiting

Trial end date:
2025-12-30

Target enrollment:

Participant gender:

Summary

A randomized, double blind, multicenter, multinational, placebo controlled, parallel group, single dose, adaptive phase II/III study (respectively Part 1 and 2). The study evaluates the efficacy and safety of a fixed dose of glenzocimab (1000 mg IV over 6 hrs including initial bolus of 15 minutes) on top of the best standard of care.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Acticor Biotech

Treatments:

Glenzocimab